Literature DB >> 28040491

Temporal processsing demands in the HIV-1 transgenic rat: Amodal gating and implications for diagnostics.

Kristen A McLaurin1, Rosemarie M Booze1, Charles F Mactutus2.   

Abstract

Despite the success of combination antiretroviral therapy (cART), approximately 50% of HIV-1 seropositive individuals develop HIV-1 associated neurocognitive disorders (HAND). Unfortunately, point-of-care screening tools for HAND lack sensitivity and specificity, especially in low-resource countries. Temporal processing deficits have emerged as a critical underlying dimension of neurocognitive impairments observed in HIV-1 and may provide a key target for the development of a novel point-of-care screening tool for HAND. Cross-modal prepulse inhibition (PPI; i.e., auditory, visual, or tactile prepulse stimuli) and gap-prepulse inhibition (gap-PPI; i.e., auditory, visual or tactile prepulse stimuli), two translational experimental paradigms, were used to assess the nature of temporal processing deficits in the HIV-1 transgenic (Tg) rat. Cross-modal PPI revealed a relative insensitivity to the manipulation of interstimulus interval (ISI) in HIV-1 Tg rats in comparison to controls, regardless of prestimulus modality. Gap-PPI revealed differential sensitivity to the manipulation of ISI, independent of modality, in HIV-1 Tg rats in comparison to control animals. Manipulation of context (i.e., concurrent visual or tactile stimulus) in auditory PPI revealed a differential sensitivity in HIV-1 Tg animals compared to controls. The potential utility of amodal temporal processing deficits as an innovative point-of-care screening tool was explored using a discriminant function analysis, which diagnosed the presence of the HIV-1 transgene with 97.4% accuracy. Thus, the presence of amodal temporal processing deficits in the HIV-1 Tg rat supports the hypothesis of a central temporal processing deficit in HIV-1 seropositive individuals, heralding an opportunity for the development of a point-of-care screening tool for HAND.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  Amodal gating; HIV-1 associated neurocognitive disorders; Point-of-care screening tool; Temporal processing

Mesh:

Year:  2016        PMID: 28040491      PMCID: PMC5673258          DOI: 10.1016/j.ijdevneu.2016.11.004

Source DB:  PubMed          Journal:  Int J Dev Neurosci        ISSN: 0736-5748            Impact factor:   2.457


  65 in total

1.  Electrophysiological manifestations in adults with HIV/AIDS submitted and not submitted to antiretroviral therapy.

Authors:  Carla Gentile Matas; Sara Manami Silva; Bruna de Almeida Marcon; Isabela Crivellaro Gonçalves
Journal:  Pro Fono       Date:  2010 Apr-Jun

Review 2.  Human immunodeficiency virus-associated neurocognitive disorders: Mind the gap.

Authors:  Justin C McArthur; Joseph Steiner; Ned Sacktor; Avi Nath
Journal:  Ann Neurol       Date:  2010-06       Impact factor: 10.422

3.  Evaluating cognitive impairment in the clinical setting: practical screening and assessment tools.

Authors:  Victor G Valcour
Journal:  Top Antivir Med       Date:  2011-12

4.  Selective developmental alterations in The HIV-1 transgenic rat: Opportunities for diagnosis of pediatric HIV-1.

Authors:  Kristen A McLaurin; Rosemarie M Booze; Charles F Mactutus
Journal:  J Neurovirol       Date:  2016-08-18       Impact factor: 2.643

5.  HIV-associated neurocognitive disorder in HIV-infected Koreans: the Korean NeuroAIDS Project.

Authors:  N S Ku; Y Lee; J Y Ahn; J E Song; M H Kim; S B Kim; S J Jeong; K-W Hong; E Kim; S H Han; J Y Song; H J Cheong; Y G Song; W J Kim; J M Kim; D M Smith; J Y Choi
Journal:  HIV Med       Date:  2014-02-24       Impact factor: 3.180

Review 6.  Evolving clinical phenotypes in HIV-associated neurocognitive disorders.

Authors:  Ned Sacktor; Kevin Robertson
Journal:  Curr Opin HIV AIDS       Date:  2014-11       Impact factor: 4.283

7.  HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors.

Authors:  Robert K Heaton; Donald R Franklin; Ronald J Ellis; J Allen McCutchan; Scott L Letendre; Shannon Leblanc; Stephanie H Corkran; Nichole A Duarte; David B Clifford; Steven P Woods; Ann C Collier; Christina M Marra; Susan Morgello; Monica Rivera Mindt; Michael J Taylor; Thomas D Marcotte; J Hampton Atkinson; Tanya Wolfson; Benjamin B Gelman; Justin C McArthur; David M Simpson; Ian Abramson; Anthony Gamst; Christine Fennema-Notestine; Terry L Jernigan; Joseph Wong; Igor Grant
Journal:  J Neurovirol       Date:  2010-12-21       Impact factor: 2.643

8.  Progression of temporal processing deficits in the HIV-1 transgenic rat.

Authors:  Kristen A McLaurin; Rosemarie M Booze; Charles F Mactutus
Journal:  Sci Rep       Date:  2016-09-06       Impact factor: 4.379

Review 9.  Cognitive neuropsychology of HIV-associated neurocognitive disorders.

Authors:  Steven Paul Woods; David J Moore; Erica Weber; Igor Grant
Journal:  Neuropsychol Rev       Date:  2009-05-22       Impact factor: 7.444

Review 10.  Evaluation of brief screening tools for neurocognitive impairment in HIV/AIDS: a systematic review of the literature.

Authors:  Amy R Zipursky; David Gogolishvili; Sergio Rueda; Jason Brunetta; Adriana Carvalhal; Jennifer A McCombe; M John Gill; Anita Rachlis; Ron Rosenes; Gordon Arbess; Thomas Marcotte; Sean B Rourke
Journal:  AIDS       Date:  2013-09-24       Impact factor: 4.177

View more
  16 in total

1.  Evolution of the HIV-1 transgenic rat: utility in assessing the progression of HIV-1-associated neurocognitive disorders.

Authors:  Kristen A McLaurin; Rosemarie M Booze; Charles F Mactutus
Journal:  J Neurovirol       Date:  2017-07-20       Impact factor: 2.643

Review 2.  An Empirical Mediation Analysis of Mechanisms Underlying HIV-1-Associated Neurocognitive Disorders.

Authors:  Kristen A McLaurin; Charles F Mactutus; Rosemarie M Booze; Amanda J Fairchild
Journal:  Brain Res       Date:  2019-09-09       Impact factor: 3.252

3.  Diagnostic and prognostic biomarkers for HAND.

Authors:  Kristen A McLaurin; Rosemarie M Booze; Charles F Mactutus
Journal:  J Neurovirol       Date:  2019-01-03       Impact factor: 2.643

4.  The Power of Interstimulus Interval for the Assessment of Temporal Processing in Rodents.

Authors:  Kristen A McLaurin; Landhing M Moran; Hailong Li; Rosemarie M Booze; Charles F Mactutus
Journal:  J Vis Exp       Date:  2019-04-19       Impact factor: 1.355

5.  Dose-dependent neurocognitive deficits following postnatal day 10 HIV-1 viral protein exposure: Relationship to hippocampal anatomy parameters.

Authors:  Sylvia Fitting; Kristen A McLaurin; Rosemarie M Booze; Charles F Mactutus
Journal:  Int J Dev Neurosci       Date:  2017-10-27       Impact factor: 2.457

6.  Combined HIV-1 Tat and oxycodone activate the hypothalamic-pituitary-adrenal and -gonadal axes and promote psychomotor, affective, and cognitive dysfunction in female mice.

Authors:  Mohammed F Salahuddin; Alaa N Qrareya; Fakhri Mahdi; Dejun Jackson; Matthew Foster; Tamara Vujanovic; J Gaston Box; Jason J Paris
Journal:  Horm Behav       Date:  2019-12-13       Impact factor: 3.587

7.  Unraveling Individual Differences In The HIV-1 Transgenic Rat: Therapeutic Efficacy Of Methylphenidate.

Authors:  Kristen A McLaurin; Hailong Li; Rosemarie M Booze; Amanda J Fairchild; Charles F Mactutus
Journal:  Sci Rep       Date:  2018-01-09       Impact factor: 4.379

8.  Neurorestoration of Sustained Attention in a Model of HIV-1 Associated Neurocognitive Disorders.

Authors:  Landhing M Moran; Kristen A McLaurin; Rosemarie M Booze; Charles F Mactutus
Journal:  Front Behav Neurosci       Date:  2019-08-06       Impact factor: 3.558

9.  Microglial HIV-1 Expression: Role in HIV-1 Associated Neurocognitive Disorders.

Authors:  Hailong Li; Kristen A McLaurin; Jessica M Illenberger; Charles F Mactutus; Rosemarie M Booze
Journal:  Viruses       Date:  2021-05-17       Impact factor: 5.048

10.  Sex Matters: Robust Sex Differences in Signal Detection in the HIV-1 Transgenic Rat.

Authors:  Kristen A McLaurin; Rosemarie M Booze; Charles F Mactutus; Amanda J Fairchild
Journal:  Front Behav Neurosci       Date:  2017-11-06       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.